Tumor necrosis factor α reduces butyrate oxidation in vitro in human colonic mucosa: A link from inflammatory process to mucosal damage?

Inflammatory Bowel Diseases

Volumn 11, Issue 6, 2005, Pages 559-566

  Nancey, Stéphane ^a   Moussata, Driffa ^a   Graber, Ivan ^a   Claudel, Sylvette ^a   Saurin, Jean Christophe ^a   Flourié, Bernard ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

oxidation; Butyrate; Glucose; Inflammatory bowel disease; Tumor necrosis factor

Indexed keywords

BUTYRIC ACID; CARBON 14; CARBON DIOXIDE; CYTOKINE; GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRYPAN BLUE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL METABOLISM; CLINICAL ARTICLE; COLITIS; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENERGY METABOLISM; ENERGY RESOURCE; ENTERITIS; ENZYME RELEASE; FATTY ACID OXIDATION; FEMALE; FERMENTATION; GLUCOSE OXIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL;

AGED; BACTERIA; BIOPSY; BUTYRATES; CASE-CONTROL STUDIES; COLON; COLONOSCOPY; CYTOKINES; FEMALE; FERMENTATION; GLUCOSE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OXIDATION-REDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20444440260     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000161918.04760.f3     Document Type: Article

References (70)

1. Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21:793-798.
2. Binder HJ, Mehta P. Short chain fatty acids stimulate active Na and Cl absorption in vitro in the rat distal colon. Gastroenterology. 1989;96:989-996.
3. Finnie IA, Dwarakanath AD, Taylor BA, et al. Colonic mucin synthesis is increased by butyrate sodium. Gut. 1995;36:93-99.
4. Roediger WEW, Kapaniris O, Millard S. Lipogenesis from n-butyrate in colonocytes. Action of reducing agents and 5-amino salicylic acid with relevance to ulcerative colitis. Mol Cell Biochem. 1992;118:113-118.
5. Ramakrishna BS, Roberts-Thomson IC, Pannall PR, et al. Impaired sulphation of phenol by the colonic mucosa in quiescent and active ulcerative colitis. Gut. 1991;32:46-49.
6. Balfour Sartor R. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994;106:533-539.
7. Cominelli F, Dinarello CA. Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease. Biotherapy. 1989;1:369-375.
8. Brynskov J, Tvede N, Andersen CB, et al. Increased concentrations of interleukin 1β, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut. 1992;33:55-58.
9. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut. 1990;31:686-689.
10. Mitsuyama K, Sasaki E, Toyonaga A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion. 1991;50:104-111.
11. Kusugami K, Fukatsu A, Tanimoto M, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci. 1995;40:949-959.
12. Sun X, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest. 1988;81:1328-1331.
13. Remick D, Kunkel S. Pathophysiologic alterations induced by tumor necrosis factor. Int Rev Exp Pathol. 1993;34:7-25.
14. Patton JS, Peters PM, McCabe J, et al. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-α in rodents. J Clin Invest. 1987;80:1587-1596.
15. Butler LD, Layman NK, Cain RL, et al. Interleukin-1 induced pathophysiology: induction of cytokine development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol. 1989;53:400-421.
16. Jongen-Lavrencic M, Peeters HRM, Rozemuller H, et al. IL-6-induced anaemia in rats: possible pathogenetic implications for anaemia observed in chronic inflammations. Clin Exp Immunol. 1996;103:328-334.
17. Roediger WEW. The colonic epithelium in ulcerative colitis: an energy deficiency disease. Lancet. 1980;2:712-715.
18. Duffy MM, Regan MC, Ravichandran P, et al. Mucosal metabolism in ulcerative colitis and Crohn's disease. Dis Colon Rectum. 1998;41:1399-1405.
19. Ahmad M, Krishnan S, Ramakrishna B, et al. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut. 2000;46:493-499.
20. Den Hond E, Hiele M, Evenepoet P, et al. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology. 1998;115:584-590.
21. Simpson EJ, Chapman MAS, Dawson J, et al. In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. Gut. 2000;46:73-77.
22. Kruse PF, Patterson MK. Tissue Culture: Methods and Applications. New York: Academic Press; 1973.
23. Perret V, Lev R, Pigman W. Simple method for the preparation of single cell suspensions from normal and tumorous rat colonic mucosa. Gut. 1977;18:382-385.
24. Korzeniewski C, Callewaert D. An enzyme-release assay for natural cytotoxicity. J Immunol Methods. 1983;64:313-320.
25. Finnie IA, Taylor BA, Rhodes JM, et al. Heal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut. 1993;34:1552-1558.
26. Targan SR, Deem RL, Shanahan F, et al. Role of mucosal T-cell generated cytokines in epithelial cell injury. Immunol Res. 1991;10:472-478.
27. Mahida YR, Wu K, Jewell DP. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut. 1989;30:1362-1370.
28. Allison MC, Poulter LW. Changes in phenotypically distinct mucosal macrophage population may be a prerequisite for development of inflammatory bowel disease. Clin Exp Immunol. 1991;85:504-509.
29. Conner EM, Brand SJ, Davis JM, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression. Inflamm Bowel Dis. 1996;2:133-147.
30. Perner A, Rask-Madsen J. The potential role of nitric oxide in chronic inflammatory bowel disorders. Aliment Pharmacol Ther. 1999;13:135-144.
31. Pender SL, Tickle SP, Docherty AJP, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997;158:1582-1590.
32. Graham MF, Willey A, Adams J, et al. Interleukin 1β down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells. Gastroenterology. 1996;110:344-350.
33. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989;44:153-205.
34. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543-1549.
35. Luger TA, Krutmann J, Kirnbauer R, et al. IFN/IL-6 augments the activity of human natural killer cells. J Immunol. 1989;143:1206-1209.
36. Garside P. Cytokines in experimental colitis. Clin Exp Immunol. 1999;118:337-339.
37. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709.
38. Dealtry GB, Naylor MS, Fiers W, et al. The effect of recombinant tumor necrosis factor on growth and macromolecular synthesis of human epithelial cells. Exp Cell Res. 1987;170:428-438.
39. Schiller JH, Bittner G, Storer B, et al. Synergistic antitumor effects of tumor necrosis factor and interferon on human colon carcinoma cell lines. Cancer Res. 1987;47:2809-2813.
40. Talmagde JE, Bowersox O, Tribble H, et al. Toxicity of tumor necrosis factor is synergistic with γ-interferon and can be reduced with cyclooxygenase inhibitors. Am J Pathol. 1987;128:410-425.
41. Deem RL, Shanahan F, Targan S. Triggered human mucosal T cells release tumor necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol. 1991;83:79-84.
42. Rath PC, Aggarwal BB. TNF-induced signalling in apoptosis. J Clin Immunol. 1999;19:350-356.
43. Hiribarren A, Heyman M, L'Helgouac'h A, et al. Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A. Gut. 1993;34:616-620.
44. Pedersen G, Saermark T, Horn T, et al. Cytokine-induced impairment of short-chain fatty acid oxidation and viability in human colonic epithelial cells. Cytokine. 2000;12:1400-1404.
45. Heyman M, Darmon N, Dupont C, et al. Mononuclear cells from infants allergic to cow's milk secrete tumor necrosis factor α, altering intestinal function. Gastroenterology. 1994;106:1514-1523.
46. Rodriguez P, Heyman M, Candalh C, et al. Tumor necrosis factor-α induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers. Cytokine. 1995;7:441-448.
47. 2. Am J Physiol. 1996;271:669-674.
48. Mc Kay. Cytokine regulation of epithelial permeability and ion transport. Gut. 1999;44:283-289.
49. Singh G, Chaudry KI, Morrison MH, et al. Tumor necrosis factor depresses gut absorptive function. Circ Shock. 1993;39:279-284.
50. Garside P, Bunce C, Tomlinson RC, et al. Analysis of enteropathy induced by tumor necrosis factor α. Cytokine. 1993;5:24-30.
51. Youngman KR, Simon PL, West GA, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology. 1993;104:749-758.
52. Nicholls S, Stephens S, Braegger S, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol. 1993;46:757-760.
53. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996;16:144-149.
54. Carty E, De Brabander M, Feakins RM, et al. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut. 2000;46:487-492.
55. Chapman MAS, Grahn MF, Giamundo P, et al. New technique to measure mucosal metabolism and its use to map substrate utilization in the healthy human large bowel. Br J Surg. 1993;80:445-449.
56. Pedersen G, Saermark T, Bendtzen K, et al. Cultures of human colonic epithelial cells isolated from endoscopical biopsies from patients with inflammatory bowel disease. Effect of IFNγ, TNFα and IL-1β on viability, butyrate oxidation and IL-8 secretion. Autoimmunity. 2000;32:255-263.
57. Roediger WEW, Millard S. Selective inhibition of fatty acid oxidation in colonocytes by ibuprofen: a cause of colitis? Gut. 1995;36:55-59.
58. Kruh J, Dfer N, Tichonicky L. Molecular and Cellular Effects of Sodium Butyrate: Metabolism and Clinical Importance. Columbus, OH: Ross Laboratories; 1991.
59. Tarnawski AS, Szabo I. Apoptosis-programmed cell death and its relevance to gastrointestinal epithelium: survival signal from the matrix. Gastroenterology. 2001;120:294-298.
60. D'Argenio G, Cosenza V, Sorrentini I, et al. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. Gastroenterology. 1994;106:399-404.
61. Gibson PR, Rosella O, Rosella G, et al. Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro. Gastroenterology. 1994;107:410-419.
62. Aggarwal B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756.
63. Shirota K, LeDuy L, Yuan SY, et al. IL-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;58:303-308.
64. Panja A, Goldberg S, Eckmann L, et al. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol. 1998;161:3675-3684.
65. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet. 1989;i:1122-1126.
66. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J. 1990;4:3215-3223.
67. Pender SLF, Fell JME, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol. 1998;160:4098-4103.
68. Monteleone G, MacDonald TT, Wathen NC, et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology. 1999;117:1069-1077.
69. Schulze-Osthoff K, Bakker A, Vanhaesebroeck B, et al. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem. 1992;267:5317-5323.
70. Stadler J, Bentz BG, Harbrecht BG, et al. Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann Surg. 1992;216:539-546.